Interstitial lung diseases (ILDs) are a diverse group of parenchymal pulmonary disorders characterized by varying degrees of inflammation and fibrosis. When pulmonary fibrosis predominates, ILDs are especially challenging to manage and treat. Idiopathic pulmonary fibrosis (IPF), chronic hypersensitivity pneumonitis (cHP), and connective tissue disease-related ILD (CTD-ILD) are associated with significant mortality. [1] [2] [3] Other less well-characterized types of fibrotic ILD include fibrotic nonspecific interstitial pneumonia and interstitial pneumonia with autoimmune features, with a usual interstitial pneumonia (UIP) pattern. Although a conservative approach to management has been advocated in early or mild ILD, antiinflammatory and immunosuppressive therapies are considered and often prescribed when progression of CTD-ILD and cHP occurs despite the largely unproven efficacy in these disorders. A recently completed trial comparing mycophenolate mofetil with oral cyclophosphamide in systemic sclerosis-associated interstitial lung disease (SSc-ILD) showed noninferiority with mycophenolate mofetil. 4 Two novel antifibrotic agents, nintedanib and pirfenidone, which slowed lung function decline and disease progression in patients with IPF and mild to moderate lung disease, are now approved for the treatment of IPF, a generally progressive and fatal disorder. No strong recommendations can be made regarding the use of nintedanib or pirfenidone in cHP or fibrotic CTD-ILD until the safety and efficacy of these agents are formally evaluated in such populations. Adjunct therapies for patients with fibrotic ILD include oxygen to correct hypoxemia and the identification and treatment of comorbidities.
The present article reviews the most recent advances in the clinical management and medical therapy for the three common fibrotic ILDs: IPF, cHP, and CTD-ILD.
Idiopathic Pulmonary Fibrosis
IPF, the most prevalent idiopathic interstitial pneumonia, has a median survival of 3 to 5 years from diagnosis. 1, 5, 6 Although its etiology remains unknown, potential risk factors for IPF include cigarette smoking, gastroesophageal reflux, and certain environmental exposures. 7 Its pathophysiology is currently believed to involve epithelial injury with abnormal wound healing. The initial conception of the pathogenic process in IPF as partially inflammatory resulted in consideration of broad immunosuppression as a potential therapy. However, the Prednisone, Azathioprine and N-Acetylcysteine: A Study That Evaluates Response in IPF (PANTHER) trial showed that prednisone, azathioprine, and N-acetylcysteine (NAC) resulted in increased mortality compared with placebo. 8 In addition, NAC alone was not beneficial in patients with IPF who had mild to moderate impairment of lung function. 9 These studies demonstrated the necessity and ability of well-designed clinical trials to elucidate the safety and efficacy of therapy in IPF. More recently, clinical trials have focused on therapies that attenuate fibrosis.
Pirfenidone
Pirfenidone is an oral agent recently approved by the US Food and Drug Administration (FDA) for the treatment of IPF (Table 1) . It is a pyridone analogue with multiple potential mechanisms of action, including the inhibition of cytokines that play key roles in fibrosis and inflammation such as transforming growth factor-b (TGF-b) and tumor necrosis factor-a. [10] [11] [12] [13] Oral administration results in peak serum concentrations at 30 min in fasting older adults or approximately 4 h when taken with food; its mean elimination half-life approaches 2.4 h. 14, 15 Five randomized, double-blind, placebo-controlled trials have evaluated the clinical efficacy and safety of pirfenidone in patients with IPF. The first such Phase 2 trial showed that patients treated with pirfenidone 1,800 mg/d experienced a significant reduction in the decline of their vital capacity at 9 months and were free of IPF exacerbations. 16 These findings prompted a Phase 3 clinical trial 17 using different doses of pirfenidone that reported a significantly reduced decline in the vital capacity of patients taking the highest dose of pirfenidone compared with placebo. Progression-free survival defined as time until death and/or $ 10% decline in vital capacity was greater in the pirfenidone group. These studies led to the approval of pirfenidone for the treatment of IPF in Japan in 2008. (Table 2) . 19, 20 In CAPACITY-004, patients treated with pirfenidone 2,403 mg/d had a significantly reduced decline in percent predicted FVC of -8.0% vs -12.4% in the placebo group at 72 weeks. CAPACITY-006 found no significant difference in change in FVC between these groups. The decline in the 6-min walk test was significantly reduced in patients taking 2,403 mg/d in the pooled analysis of both trials. Assessment of data from both CAPACITY and the Japanese trials led to the approval of pirfenidone in the European Union in 2011. 21 The FDA requested an additional study to support the approval of pirfenidone for use in IPF, which led to the Assessment of Pirfenidone to Confirm Efficacy and Safety in Idiopathic Pulmonary Fibrosis (ASCEND) trial 22 (Table 2) . This trial used a modified study design with a centralized confirmation of diagnosis that included review of all high-resolution CT (HRCT) scans and a lung biopsy if the CT scan showed possible rather than definite UIP. The eligibility criteria were also modified to enroll patients at a higher risk of disease progression than those in the CAPACITY trials by allowing a lower diffusion capacity of the lung for carbon monoxide (DLCO) of 30% rather than 35% predicted and requiring a FEV 1 /FVC ratio > 0.80. This study reported a smaller mean decline from baseline in FVC of -235 mL in those receiving pirfenidone compared with -428 mL in the placebo group (P < .001) at 52 weeks. A reduction was noted in the proportion of patients with a $ 10% decline in the percent predicted FVC or death in the pirfenidone vs placebo groups. Patients in the pirfenidone group also had a significantly improved progression-free survival (defined as time to first occurrence of a $ 10% reduction in the percent predicted FVC, decrease in the 6-min walk test of $ 50 m, or occurrence of death) and a significantly smaller decline in their 6-min walk test over the 1-year period compared with placebo. There were no significant differences in dyspnea, all-cause mortality, or IPF-related mortality. Major side effects of pirfenidone compared with placebo included nausea, vomiting, dyspepsia, anorexia, and skin rash.
A pooled population of 1,247 patients enrolled in the ASCEND and both CAPACITY trials was analyzed for all-cause mortality by using prespecified criteria. A significant reduction in IPF-related mortality (hazard 19 Rash and photosensitivity occurred in 16% and 9% of treated patients, respectively. Since drug approval, agranulocytosis and angioedema have been identified as rare drug-related adverse events.
Nintedanib
Nintedanib ethanesulfonate is an orally available intracellular tyrosine kinase inhibitor that targets several growth factor receptors ( Table 1) . 27 Its action on the adenosine 5 0 -triphosphate-binding site of the vascular endothelial growth factor receptor 2 kinase domain results in the inhibition of vascular endothelial growth factor receptor 1 to 3, fibroblast growth factor receptor 1 to 3, and platelet-derived growth factor receptor-a and -
b.
28-30 Recent studies of nintedanib reported inhibitory activity against the proliferation of human endothelial cells stimulated by vascular endothelial growth factor and fibroblast growth factor and vascular smooth muscle cells stimulated by platelet-derived growth factor. In myofibroblasts from patients with IPF, nintedanib counteracted the profibrotic effects of TGF-b1, thereby increasing expression of matrix metalloproteinase and reducing cell proliferation and collagen secretion.
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In the To Improve Pulmonary Fibrosis With BIBF 1120 (TOMORROW) Phase 2 trial, the efficacy and safety of four oral doses of nintedanib were compared vs placebo in patients with IPF 32 ( . Prespecified pooled analysis of both studies revealed no significant differences between the nintedanib and placebo groups in the adjusted mean change of SGRQ score or death from any cause (5.5% vs 7.8%; P ¼ .14). Patients treated with nintedanib demonstrated more frequent adverse events compared with those receiving placebo. These adverse events included elevated liver enzyme levels (4.9%-5.2% vs 0.5%-0.9%) and myocardial infarction (1.5%-1.6% vs 0.5%). Diarrhea was experienced by 62% of patients who received nintedanib but was associated with medication discontinuation in < 5% of patients. These results led to FDA approval in 2014 of nintedanib for the treatment of patients with IPF, with subsequent European Union approval in 2015.
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A recent study analyzed the treatment effects of nintedanib in patient subgroups by using pooled data from the INPULSIS trials. 36 There were no differences in the prespecified primary end point of yearly FVC decline or key secondary end points of SGRQ change from baseline and time to first acute exacerbation in patients treated with nintedanib when grouped according to age, sex, race, baseline predicted FVC (< 70% vs > 70%), and baseline SGRQ. Although the studies were not designed to assess the treatment effect of nintedanib in these populations, the findings confirm equivalent efficacy of nintedanib across these different subgroups of patients with IPF.
Recommended Approach to Therapy in IPF
A diagnosis of IPF requires a multidisciplinary assessment according to established guidelines. 7 The recently updated American Thoracic Society/European Respiratory Society/Japanese Respiratory Society/Latin journal.publications.chestnet.org
American Thoracic Association clinical practice guidelines for the treatment of IPF recommend against the use of warfarin, imatinib, ambrisentan, or a combination of prednisone, azathioprine, and NAC. 37 Due to moderate confidence in the effect estimates associated with the use of pirfenidone or nintedanib, these guidelines provide a conditional recommendation for their use in IPF treatment. Based on data from clinical trials of nintedanib or pirfenidone, patients can anticipate a slowing in disease progression (as assessed according to FVC) and may note some improvement in symptoms. There are no data to guide initiation of therapy in elderly patients or in those with very mild or severely reduced lung function or significant comorbidities (these patients did not fit the inclusion criteria of the pivotal trials).
A recent meta-analysis evaluating pharmacotherapies across multiple IPF studies demonstrated similar effects of nintedanib and pirfenidone on FVC decline and respiratory-and all-cause mortality. 38 The decision regarding which of the two agents to start should be based on data from the clinical trials validating these therapies, the practitioner's assessment of patient comorbidities and preferences, and the likelihood of potential adverse events given their relative equivalence in efficacy.
The observed difference in the relative reduction in FVC decline between nintedanib (52.2%) and pirfenidone (45.1%) may be attributable to the different statistical methods used to analyze the data. Because the pathogenesis of IPF seems to involve distinct pathways, the safety and efficacy of combination therapy with nintedanib and pirfenidone warrant further study. 39 A multinational, randomized, openlabel, parallel-group study was initiated to evaluate nintedanib in patients with IPF when administered in combination with pirfenidone, compared with nintedanib therapy alone. 40 Patients prescribed nintedanib or pirfenidone should be educated on potential adverse effects, need for dose adjustments, behavioral modifications, and therapies to improve tolerability and the need for regular monitoring of hepatic function ( At initiation of pirfenidone, dosage should be titrated starting with one pill (267 mg) three times daily for 1 week, then two pills thrice daily for 1 week, then three pills thrice daily. Gastrointestinal complaints such as nausea, vomiting and dyspepsia, and skin rash are the most common adverse effects; dizziness, fatigue, and anorexia may also be noted. Adverse effects have been associated with peak plasma concentration and tend to develop early during therapy with the exception of phototoxicity, which can develop at any time.
Taking pirfenidone with meals may reduce gastrointestinal symptoms. Dermatologic reactions, which occurred in 28% of patients in the ASCEND trial, are most often due to phototoxicity. 15, 22 Avoiding exposure to sunlight and routine use of sunscreen may prevent this reaction. Phototoxicity may be managed by temporary dose reduction or cessation and resumption of full-dose therapy after resolution of the rash. Pirfenidone is metabolized by hepatic enzyme cytochrome P450 1A2; thus, other drugs also metabolized by this enzyme such as fluvoxamine should be used with caution because they may increase blood levels of pirfenidone. 22 Prescribing guidelines recommend decreasing the dose in the setting of coadministration with moderate cytochrome P450 1A2 inhibitors such as ciprofloxacin.
Stem Cells and Cell-based Therapies
An increasing number of clinical trials highlight the role of mesenchymal stem cells (MSC) as a potential therapeutic agent for fibrotic lung disease. These multipotent cells of stromal origin, which may be isolated from umbilical cord blood, placenta, adipose tissue, Wharton's jelly, or lung tissue, have the ability to self-renew and give rise to progeny that can differentiate into various cell lineages.
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The AETHER study, a Phase 1, randomized, doubleblinded trial, evaluated the safety and tolerability of IV bone marrow-derived human MSC for patients with IPF in a pilot study. 44 The interim safety analysis of this 60-week study demonstrated no treatment-emergent adverse events in nine subjects with mild to moderate IPF, randomized into three treatment groups. 45 Chambers et al 46 showed that 15% of these patients had autoimmune features, which independently predicted mortality (HR, 4.45 [95% CI, 1.43 to 13.88]; P ¼ .01).
Although systemic corticosteroids are often used in the treatment of cHP based on expert opinion, the longterm efficacy of these agents has not been validated by 
Connective Tissue Disease-related ILDs
Connective tissue diseases are frequently complicated by ILDs, which when fibrotic and progressive, are a major contributor to mortality. The heterogeneous nature of CTD-ILDs and lack of coordinated care networks have limited the performance of rigorous clinical trials; thus, evidence regarding the safety and efficacy data of most therapy prescribed for patients with CTD-ILD are either of poor quality or lacking. 62 Hu et al 63 and Fischer et al 64 retrospectively evaluated 1,044 patients with CTD-ILD, including patients with the recently proposed "interstitial pneumonia with autoimmune features." Although diagnosis was delayed in 32%, overall prognosis was favorable, and most deaths were attributed to acute exacerbation of CTD-ILD. Disease remission occurred in > 75% with the use of glucocorticoid, antirheumatic, and antifibrotic therapy. Recent guidelines by the Outcome Measures in Rheumatology CTD-ILD working group, defining clinically meaningful disease progression and response to therapy, aim to facilitate the development of welldesigned, multicenter, randomized clinical trials.
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Systemic Sclerosis-associated Interstitial Lung Disease
In patients with SSc-ILD, radiographic fibrosis is common. 66, 67 Two landmark studies, the Fibrosing Alveolitis in Scleroderma Trial (FAST) and the Scleroderma Lung Study (SLS), have suggested benefit with immunosuppressive treatment. 68, 69 The FAST study demonstrated a favorable change in the FVC in patients treated with low-dose prednisolone and IV cyclophosphamide followed by azathioprine.
The SLS found a reduced decline in FVC and improved quality of life in patients with SSc-ILD when treated with oral cyclophosphamide for 12 months; benefits were absent at 24 months 68, 70 (Table 2) . Preliminary data from a subsequent study comparing the use of oral mycophenolate mofetil vs oral cyclophosphamide in patients with SSc-ILD found that mycophenolate mofetil had comparable efficacy, fewer adverse events, and a lower incidence of treatment failures than cyclophosphamide. 71 Results from the recently completed Safety and Tolerability of Pirfenidone in Patients With Systemic Sclerosis-Related Interstitial Lung Disease (LOTUSS) study 72 showed that pirfenidone was generally well tolerated in patients with SSc-ILD. 73 Khanna et al 73, 74 evaluated the safety and tolerability of
pirfenidone in an open-label, 16-week study of 63 patients with SSc-ILD. At study termination, the median change from baseline in percent predicted FVC was -0.5%, whereas the median change from baseline in percent predicted DLCO was 1.5%. Their study found that pirfenidone was generally well tolerated in patients with SSc-ILD. The association of scleroderma renal crisis with the use of moderate to high doses of corticosteroids limits their utility in systemic sclerosis. 75 A nested casecontrol study by the European Scleroderma Trial and Research (EUSTAR) group showed that in patients with SSc-ILD, rituximab prevented progressive decline in FVC compared with matched control subjects (0.4% AE 4.4% vs -7.7% AE 3.6%; P ¼ .02). 76 A randomized, double-blind, placebo-controlled Phase 3 trial evaluating the efficacy and safety of nintedanib 150 mg bid in treating patients with SSc-ILD is currently active and recruiting participants as of June 27, 2016. have demonstrated lung function improvement with oral cyclophosphamide and the ability to taper corticosteroid treatment with mycophenolate mofetil 70, 81, 82 (Table 2) . Cyclosporine has been shown to have efficacy in small retrospective studies of patients with antisynthetase syndrome associated-ILD refractory to corticosteroids. 83, 84 There is evidence of benefit associated with the use of tacrolimus in patients with IIM or antisynthetase syndrome-ILD. 84, 85 In the aforementioned study by Keir et al, 60 rituximab was associated with improved FVC and stabilization of DLCO in patients with IIM-associated ILD. However, the treatment effects suggested by these small retrospective studies require validation in larger, prospective randomized clinical trials.
Determining whether and when to start therapy in CTD-ILD is challenging for multiple reasons. Some patients have mild, stable ILD that does not benefit from therapy, whereas ILD in the setting of an IIM may be rapidly progressive and improve with the early use of multimodality therapy. 62 Immunosuppression with corticosteroids (Table 1) has historically been the mainstay of therapy in CTD-ILD, with expert opinion increasingly favoring adding an immunosuppressive agent when ILD is progressive or severe. Because CTD-ILD can be associated with a UIP pattern on HRCT, it is important to obtain an accurate etiologic diagnosis for prognostic purposes and because immunomodulatory therapy may be detrimental in UIP/IPF. In SSc-ILD, a reduced FVC or advanced fibrosis on HRCT scan are associated with risk of death. 86 The efficacy of immunomodulatory agents in advanced fibrosis among patients with CTD-ILD remains unclear and should be carefully weighed against their potential for adverse effects. Guidelines have been formulated for monitoring patients with diffuse interstitial and inflammatory ILD (including CTD-ILD) who are undergoing immunosuppressive therapy. 87 Patients taking prednisone $ 20 mg/d or other immunosuppressive medication should receive prophylactic therapy for Pneumocystis jirovecii pneumonia 88 and undergo periodic bone health evaluations. 89 In patients with CTD-ILD, the therapeutic effect of the newer antifibrotic agents, nintedanib and pirfenidone, remains unknown. Those with very advanced fibrosis may be candidates for lung transplantation.
Assessment and Treatment of Comorbidities in Fibrotic Lung Disease
Identification and treatment of the comorbidities that occur with fibrotic ILD may improve quality of life and outcomes (Table 4) . 90 Many patients with IPF, and some patients with CTD-ILD, have radiographic evidence of coexisting emphysema referred to as combined pulmonary fibrosis and emphysema. 91, 92 These patients often demonstrate a disproportionate decrease in DLCO compared with lung volumes, with flow rates that are relatively preserved. Smoking cessation is imperative.
Inhaled bronchodilators and inhaled corticosteroids may be beneficial in individual cases.
The risk of lung cancer is increased in IPF and is reported in patients with other forms of fibrotic lung disease, especially systemic sclerosis-associated and rheumatoid arthritis. 93 It is associated with a further reduction in life expectancy. [93] [94] [95] Although these patients may be asymptomatic, weight loss and hemoptysis should heighten suspicion and prompt further evaluation. Surgical resection, chemotherapy, and/or radiation therapy may be poorly tolerated and associated with a more rapid decline in lung function.
Patients with fibrotic ILD have an increased risk for VTE. Therefore, acute or subacute worsening should prompt a pulmonary embolism protocol contrast CT scan to evaluate for VTE. 96, 97 Coronary artery disease is prevalent in IPF and RA-ILD and is associated with worse outcomes. The risk of prolonged antiplatelet therapy should be considered when choosing whether to insert a drug-eluting stent because this approach may complicate the management of patients who are candidates for lung transplantation and those undergoing nintedanib therapy.
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Chronic fibrotic lung diseases are complicated by depression and anxiety, 101, 102 which have been associated with symptom severity and are key predictors of the quality of life. Screening for depression to determine the need for cognitive behavioral therapy or antidepressant medication may be helpful. Data suggest supplemental oxygen and pulmonary rehabilitation may ameliorate dyspnea and depression in patients with ILD. 103 Pulmonary rehabilitation is also useful in the treatment of comorbidities such as skeletal muscle dysfunction and deconditioning, frequently associated with chronic inflammatory states and sedentariness. 104, 105 In patients with IPF and hypoxemia, exercise training may maintain oxygen uptake while improving quality of life. 106, 107 Current guidelines support regular assessment for hypoxemia with prescription of oxygen for those with oxygen saturation < 89% at rest or with exercise. There is limited evidence regarding the use of nintedanib or pirfenidone in lung transplant recipients who develop posttransplant fibrosis or chronic lung allograft dysfunction. Some lung transplant centers are concerned that antifibrotic agents may interfere with the posttransplant healing process, and they therefore recommend cessation of pirfenidone or nintedanib 1 or 2 months prior to lung transplantation. A randomized controlled trial in this population is in progress. 129 There are few data on the perioperative use of these medications in patients undergoing lung transplantation.
Conclusions
The symptom burden and high mortality associated with fibrotic ILD have inspired the search for novel and effective treatment options ( Table 5 ). The recent approval of nintedanib and pirfenidone for the treatment of IPF potentially heralds the onset of an era in which effective therapies become available for patients with IPF. Although cell-based therapies with MSCs have been safely administered in Phase 1 clinical trials in IPF, to date there is no evidence of therapeutic benefit. 42, 46, 47 As newer agents are studied, either as stand-alone treatment or in combination for their efficacy in halting and potentially reversing the progression of fibrotic ILD, continued attention should be paid to adjunct therapies that may significantly improve quality of life and clinical outcomes in these patients. journal.publications.chestnet.org
